Stock INVA INNOVIVA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Innoviva, Inc.

Equities

INVA

US45781M1018

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
15.26 USD +1.80% Intraday chart for Innoviva, Inc. +2.07% -4.86%
Apr. 24 Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 CI
Mar. 04 Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,434 1,256 1,199 924.6 1,028 964.8 - -
Enterprise Value (EV) 1 1,460 1,395 1,392 1,174 1,281 1,152 1,071 991.5
P/E ratio 9.9 x - - 5.59 x - - - -
Yield - - - - - - - -
Capitalization / Revenue 5.49 x 3.73 x 3.06 x 2.79 x 3.31 x 3.21 x 2.89 x 2.69 x
EV / Revenue 5.6 x 4.14 x 3.55 x 3.54 x 4.13 x 3.83 x 3.21 x 2.76 x
EV / EBITDA 5.61 x 4.17 x 3.58 x 5.31 x - 10 x 8.18 x 7.4 x
EV / FCF 5,672,594 x - - - - - - -
FCF Yield 0% - - - - - - -
Price to Book 4.57 x 2.33 x 2.89 x 1.62 x - - - -
Nbr of stocks (in thousands) 101,279 101,392 69,492 69,783 64,087 63,227 - -
Reference price 2 14.16 12.39 17.25 13.25 16.04 15.26 15.26 15.26
Announcement Date 2/5/20 2/3/21 2/9/22 2/28/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 261 336.8 391.9 331.3 310.5 300.7 333.8 359.2
EBITDA 1 260.2 335 388.9 220.9 - 115 130.9 133.9
EBIT 1 246.4 321.1 375.1 207 135.7 95.77 111.7 114.7
Operating Margin 94.39% 95.35% 95.72% 62.47% 43.7% 31.85% 33.46% 31.94%
Earnings before Tax (EBT) 232.9 - - - - - - -
Net income 157.3 - - - - - - -
Net margin 60.26% - - - - - - -
EPS 1.430 - - 2.370 - - - -
Free Cash Flow 257.4 - - - - - - -
FCF margin 98.63% - - - - - - -
FCF Conversion (EBITDA) 98.93% - - - - - - -
FCF Conversion (Net income) 163.68% - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/5/20 2/3/21 2/9/22 2/28/23 2/29/24 - - -
1USD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 90.06 108.2 67.26 65.8 76.37 80.99 67.26 85.84 68 75.81 73.14 83.8
EBITDA - 86.14 27.95 25.6 38.78 - - - - - - -
EBIT 1 - 82.55 22.53 24.18 29.9 33.48 17.94 44.04 20.63 25.56 19.33 30.24
Operating Margin - 76.28% 33.5% 36.75% 39.14% 41.34% 26.67% 51.3% 30.34% 33.72% 26.43% 36.09%
Earnings before Tax (EBT) - - 286.4 - 41.14 - - - - - - -
Net income - - 265.5 - 34.86 - - - - - - -
Net margin - - 394.79% - 45.65% - - - - - - -
EPS - - 2.800 -0.9800 0.4200 - - - - - - -
Dividend per Share - - - - - - - - - - - -
Announcement Date 4/27/22 7/27/22 11/9/22 2/28/23 5/9/23 8/2/23 11/1/23 2/29/24 - - - -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 26.3 139 193 249 253 187 106 26.7
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.101 x 0.4151 x 0.4966 x 1.129 x - 1.63 x 0.8113 x 0.1991 x
Free Cash Flow 257 - - - - - - -
ROE (net income / shareholders' equity) 67.3% 62.4% 55.7% 5.11% - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets - - - - - - - -
Book Value Per Share 3.100 5.330 5.960 8.180 - - - -
Cash Flow per Share 2.270 - - - - - - -
Capex 0.01 - - - - - - -
Capex / Sales 0% - - - - - - -
Announcement Date 2/5/20 2/3/21 2/9/22 2/28/23 2/29/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Innoviva, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
15.26 USD
Average target price
15 USD
Spread / Average Target
-1.70%
Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
INNOVIVA, INC. Stock Innoviva, Inc.
-4.86% 965M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. INVA Stock
  4. Financials Innoviva, Inc.